Deutsche Bank AG Makes New $15.02 Million Investment in Vaxcyte, Inc. $PCVX

Deutsche Bank AG bought a new position in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 258,338 shares of the company's stock, valued at approximately $15,017,000. Deutsche Bank AG owned 0.18% of Vaxcyte at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Royal Bank of Canada raised its holdings in shares of Vaxcyte by 115.2% during the 1st quarter. Royal Bank of Canada now owns 29,471 shares of the company's stock valued at $1,113,000 after buying an additional 15,774 shares during the period. Cubist Systematic Strategies LLC purchased a new position in Vaxcyte in the 1st quarter worth approximately $219,000. Caxton Associates LLP purchased a new position in Vaxcyte in the 1st quarter worth approximately $226,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Vaxcyte by 8.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 513,998 shares of the company's stock valued at $19,409,000 after acquiring an additional 41,034 shares in the last quarter. Finally, Cetera Investment Advisers grew its position in Vaxcyte by 13.8% in the second quarter. Cetera Investment Advisers now owns 7,681 shares of the company's stock valued at $250,000 after acquiring an additional 932 shares in the last quarter. Hedge funds and other institutional investors own 96.78% of the company's stock.

Vaxcyte Trading Up 2.1%

Shares of NASDAQ:PCVX opened at $62.62 on Friday. The firm has a market cap of $9.32 billion, a PE ratio of -8.21 and a beta of 1.23. The company has a fifty day simple moving average of $56.43 and a 200 day simple moving average of $55.80. Vaxcyte, Inc. has a 12-month low of $29.87 and a 12-month high of $65.00.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($1.97) EPS for the quarter, beating analysts' consensus estimates of ($2.06) by $0.09. During the same quarter in the prior year, the company earned ($1.22) EPS. As a group, equities research analysts forecast that Vaxcyte, Inc. will post -7.6 EPS for the current fiscal year.

Insider Transactions at Vaxcyte

In related news, COO Jim Wassil sold 2,250 shares of the firm's stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $53.86, for a total transaction of $121,185.00. Following the transaction, the chief operating officer directly owned 157,541 shares in the company, valued at $8,485,158.26. This trade represents a 1.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Grant Pickering sold 2,000 shares of Vaxcyte stock in a transaction on Monday, July 27th. The stock was sold at an average price of $55.65, for a total transaction of $111,300.00. Following the completion of the transaction, the chief executive officer directly owned 133,215 shares of the company's stock, valued at approximately $7,413,414.75. This represents a 1.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 120,646 shares of company stock valued at $6,570,810. 3.30% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

PCVX has been the topic of a number of recent research reports. Zacks Research raised shares of Vaxcyte from a "strong sell" rating to a "hold" rating in a research report on Wednesday, August 12th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Vaxcyte in a report on Monday, July 6th. Finally, Wall Street Zen raised shares of Vaxcyte from a "strong sell" rating to a "sell" rating in a research note on Saturday, August 8th. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $86.00.

About Vaxcyte

Vaxcyte, Inc NASDAQ: PCVX is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company's platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte's lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source